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Abstract
Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor 
receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer 
drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a 
major challenge for drug penetration in solid tumor tissues due to the complicated tumor 
microenvironment. We have constructed a recombinant protein named anti-EGFR-iRGD 
consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) 
fused to iRGD, a tumor-specific binding peptide with high permeability. Anti-EGFR-iRGD, which 
targets EGFR and αvβ3, spreads extensively throughout both the multicellular spheroids and the 
tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor 
cell lines, multicellular spheroids, and mice. Moreover, anti-EGFR-iRGD could improve 
anticancer drugs, such as doxorubicin (DOX), bevacizumab, nanoparticle permeability and 
efficacy in multicellular spheroids. This study draws attention to the importance of iRGD peptide 
in the therapeutic approach of anti-EGFR-iRGD. As a consequence, anti-EGFR-iRGD could be a 
drug candidate for cancer treatment and a useful adjunct of other anticancer drugs.
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1. Introduction
Gastric cancer is one of the world's leading causes of cancer-related death with a high 
incidence and mortality rate, particularly in Eastern Asia [1,2]. Despite recent advances in 
cancer therapy, such as chemotherapy, radiotherapy and biological immune therapy, most 
advanced malignancies still remain incurable. Thus, the research and development of new 
therapeutics is essential.
With the advent of molecular engineering and phage display technology, more antibodies 
have been explored. Antibodies have different formats and VHH as a minimal functional 
format has some advantages, such as: lower immunogenicity, facile genetic manipulation, 
high physicochemical stability, recognition of hidden antigenic sites and high expression 
levels. Therefore, there seems to be a trend in therapeutic and diagnostic antibodies towards 
smaller antigen-binding antibody formats [3,4]. The variable domain from the heavy chain 
of the antibody (VHH), often called a single domain antibody (sdAb) [5] or nanobody [6] 
due to its size in the nanometer range, is considered to be the smallest naturally derived 
antigen-binding fragment [7]. Human tumors frequently express high levels of epidermal 
growth factor receptor (EGFR), which has been associated with a poor prognosis when 
overexpressed [8]. EGFR (ErbB1, HER1) is a 170-kDa transmembrane tyrosine kinase 
receptor, overexpressed in a wide variety of human cancers including 27.4% of 511 gastric 
cancer tissues [9]. Progress in genetic engineering has guided the way for development of 
various EGFR inhibitors including monoclonal antibodies, (cetuximab, panitumumab, etc.), 
tyrosine-kinase inhibitors (gefitinib, erlotinib, lapatinib, etc.), antisense oligonucleotides and 
sdAbs [10].
Although targeted delivery of anticancer drugs to cancerous tissues shows potential in 
sparing unaffected tissues, it is still a major challenge for the targeted therapeutic to 
penetrate deep into solid tumor tissues. In solid cancers, the homeostatic regulation of 
tissues breaks down, cancer cells are in the state of hypoxia, interstitial fluid pressure 
increases [11–14], and the extracellular matrix (ECM) hinders the movement of drugs and 
molecules into the tumor tissue [15–17].
It has been reported that the tumor-penetrating and cell-internalizing peptide iRGD 
(sequence: CRGDKGPDC) contains both a RGD (Arg-Gly-Asp) domain and a CendR motif 
(R/KXXR/K). It first binds to αvβ3 and αvβ5 integrins, which are expressed highly in 
tumor vessels and many different types of cells in the tumor [18]. Subsequently, iRGD is 
proteolytically cleaved to CRGDK/R. The truncated peptide loses affinity for the primary 
receptor integrin, and binds to neuropilin-1 (NRP-1), triggering a cell internalization and 
tissue penetration pathway [19,20].
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Since Sutherland et al. [21,22] established multicellular spheroids (MCS) in the 1970s, this 
three-dimensional (3D) MCS in vitro tumor model has been demonstrated as a practical and 
simple model that reflects many of the properties of natural solid tumors. The 3D culture 
conditions in MCS can produce an ECM [23,24], which creates a major obstacle for drug 
penetration into tumor tissues. In addition, large MCS (>200 µm in diameter) have been 
demonstrated to form three different regions: proliferating periphery cell populations, a 
viable and quiescent intermediate zone, and a necrotic core from the outside in [25,26]. 
Furthermore, Minchinton et al. [27] mentioned that, MCS were an ideal platform for 
studying drug penetration, along with multilayered cell cultures and in vivo methods.
In this study, an anti-EGFR sdAb selected by phage display was used as a ligand to interact 
with EGFR. To efficiently deliver anti-EGFR sdAbs into the tumor and overcome the 
difficulty of poor penetration of anticancer drugs in solid tumors [27,28], we introduced a C-
end Rule peptide iRGD to an anti-EGFR sdAb. Afterwards, the anticancer activity of the 
recombinant proteins anti-EGFR and anti-EGFR-iRGD were examined. Penetration of anti-
EGFR and anti-EGFR-iRGD through both MCS culture system and in vivo methods was 
then evaluated. To study the effect of anti-EGFR-iRGD on drug delivery and efficacy, we 
also administered the protein as a combination therapy with several types of cancer drugs, 
such as DOX, bevacizumab, nanoparticles in a 3D multicellular spheroid model.
2. Materials and methods
2.1. Reagents, cell lines, and tumors
Doxorubicin hydrochloride (DOX) was purchased from Shenzhen Main Luck 
Pharmaceuticals Inc. (Shenzhen China). Paclitaxel liposome was obtained from Nanjing Si 
Ke Pharmaceutical Co., Ltd. (Nanjing, China), bevacizumab and cetuximab were purchased 
from Roche (Basel, Switzerland) and Merck (Darmstadt, Germany). siRNA targeting human 
EGFR mRNA (GenBank Accession No. NM_005228), integrin αv mRNA (GenBank 
Accession No. NM_001144999), and NRP-1 mRNA (GenBank Accession No. 
NM_001024628) were designed and synthesized by Guangzhou RiboBio Company 
(Guangzhou, China). Antibodies were purchased from Cell Signaling Technology (USA) 
(for human EGFR antibody), Signalway Antibody (USA) (for p-EGFR Tyr1172), Novus 
biologicals (USA) (for human αvβ3 antibody), and Abcam (USA) (for human NRP-1 
antibody). Mouse monoclonal anti-human CD31 and rat monoclonal anti-mouse CD31 were 
purchased from Gene Tech Company Limited (Shanghai, China) and BD Pharmingen (San 
Jose, California). An Alexa 594 conjugated donkey anti-mouse secondary antibody and 
donkey anti-rat secondary antibody were purchased from Abcam (USA) and Molecular 
Probes (Eugene, Oregon). Full length DNA for anti-EGFR in the vector pSJF2 was a gift 
from Dr. Shenghua Li at Tianjin International Joint Academy of Biotechnology and 
Medicine (Tianjin, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) for the cell viability assay was obtained from Sigma-Aldrich (USA). Fluorescein 
isothiocyanate (FITC) and coumarin-6, were obtained from Sigma Chemical Co (USA). All 
other chemicals were used as received without further treatment.
Human gastric adenocarcinoma cell line BGC-823, human epithelial colorectal 
adenocarcinoma cell line Caco-2, human breast adenocarcinoma cell line MCF-7 and 
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murine hepatic cancer cell line H22, were purchased from the Cell Bank of Shanghai 
Institute of Biochemistry and Cell Biology. BGC-823 and H22 were cultured in RPMI 1640 
medium supplemented with 10% fetal calf serum, while other cells were cultured in 
DMEM-medium (for MCF-7 cells) or MEM-medium (for Caco-2 cells), supplemented with 
10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin, and incubated at 
37 °C and 5% CO2 (all available from Invitrogen, Grand Island, NY, USA). All animal 
procedures were carried out in compliance with guidelines set by the Animal Care 
Committee at Drum Tower Hospital (Nanjing, China). Five million BGC-823 gastric cancer 
cells in 0.1 mL PBS were subcutaneously injected in the lower right axilla of athymic nude 
BALB/c mice (5–6 weeks, male, 18–22 g), while 5 million H22 cells were subcutaneously 
injected in the right axilla of ICR mice (4–5 weeks, male, 18–22 g) to produce xenograft 
tumors. Tumor volumes were calculated from 2 diameter measurements using a digital 
vernier caliper and the formula: tumor volume = (length × width2)/2, where length is the 
longest dimension and width is the widest dimension.
2.2. Preparation and characterization of recombinant proteins anti-EGFR and anti-EGFR-
iRGD
Recombinant proteins anti-EGFR and anti-EGFR-iRGD were prepared as follows. The anti-
EGFR sequence was cloned into the bacterial expression vector pET28a with a hexahistidine 
(His) tag placed at the N-terminus of anti-EGFR. To enhance cell- and tissue-penetration of 
anti-EGFR, oligonucleotides encoding iRGD were synthesized and ligated downstream of 
oligonucleotides encoding the anti-EGFR, with a glycine–serine linker (Asp) 4 Lys, i.e., 
G4S tag, placed in between. Both of the recombinant plasmids were confirmed by DNA 
sequencing. Proteins were expressed in Escherichia coli (E. coli) BL21 (DE3) after 
induction by isopropyl β-D-1-thiogalactopyranoside. The cells were then harvested by 
centrifugation, and suspended and disrupted by sonication. The supernatant of the cell lysate 
was further purified using nickel–nitrilotriacetic acid affinity chromatography under native 
conditions by the ÄKTA fast protein liquid chromatography system according to the 
manufacturer's instructions. The eluted fractions were analyzed by 4% to 15% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and confirmed by XIMA 
MALDI-TOF (Shimadzu Kratos, Manchester, UK). Labeled recombinant proteins were 
prepared by conjugating with FITC at the amine groups of lysine. The labeled protein was 
dialyzed and filtered (0.22 µm).
2.3. Initial model building and molecular dynamics
To exhibit recombinant proteins intuitively, 3D structures of anti-EGFR and anti-EGFR-
iRGD were modeled using the Accelrys Discovery Studio 4.0, based on the template of B39 
VHH (PDB: 4NC2_B) [29]. Molecular dynamics simulations were conducted to refine the 
modeled 3D structures with AMBER 12.0. Energy minimization was performed in order to 
remove possible poor contacts between the solute and solvent (5000 steps for the water 
molecules followed by 5000 steps for the whole system). Molecular dynamics simulations 
were then conducted at constant temperature (300 K) and pressure (1.0 atm) with a time step 
of 2 fs. After 1 ns equilibration, production simulations for all systems were conducted for 
10 ns. Other parameters can be referred to in our previous publication [30].
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2.4. Antigen–antibody binding assay and competitive binding assay
To investigate the binding profiles of recombinant proteins anti-EGFR and anti-EGFR-iRGD 
with human EGFR, surface plasmon resonance analysis was conducted as previously 
described [31]. BGC-823 cells in the logarithmic phase were seeded at a density of 50% 
confluence per well into 24-well chamber slides. Cells were transfected with 50 nmol/L 
siRNAs directed against EGFR, αvβ3 and NRP-1, respectively. Forty-eight hours later, cells 
were blocked in phosphate-buffered saline (PBS) supplemented with 5% bovine serum 
albumin and then incubated at 37 °C with FITC-labeled anti-EGFR-iRGD for 1 h. The cells 
were then washed three times with PBS (pH 7.4) and fixed before labeling the nuclei with 
Hoechst 33258. Next, the cells were observed with a laser scanning confocal microscope 
(LSCM) (Zeiss LSM 710). Simultaneously, BGC-823 cells of the same treatment group 
were harvested and analyzed using a FACScan laser flow cytometer (Guava easycyteHT, 
Millipore, CA). The competitive binding assay was done as follows: BGC-823 cells were 
transfected with siRNAs and blocked with 5% bovine serum albumin as described above. 
The cells were then incubated with a sub-saturated concentration of anti-EGFR-iRGD-FITC 
and the appropriate concentration of competing EGFR monoclonal antibody cetuximab or 
iRGD at 37 °C for 1 h. After fixing and nucleus staining, the cells were observed with a 
fluorescence microscope. Similarly, with the same treatment of competing cetuximab or 
iRGD, the alterations of the mean channel fluorescence were analyzed by a FACScan laser 
flow cytometer.
2.5. Formation of BGC823 MCS and growth inhibition study in MCS
In order to produce MCS, matrigel (BD Bioscience, USA) was used as previously described 
[32]. A layer of matrigel (300 µL/well) was coated on the bottom of a 24-well plate at 4 °C 
and later put in a 37 °C atmosphere for 30 min to assure that the matrigel had solidified. 
BGC-823 monolayer cells incubated as mentioned above were trypsinized and harvested to 
give a single-cell suspension. In this case, 5 × 105 cells in 1 mL of RPMI 1640 medium were 
placed in a well of the pre-treated 24-well plate. Cells were incubated at 37 °C in a 5% CO2 
humidified atmosphere and the culture medium was replaced every day. BGC-823 MCS 
(approximately 200 µm in diameter) formed spontaneously in 7 days.
Tumor MCS with 3D architecture are often used to predict the drug antitumor effect as an 
ideal platform mimicking solid tumors [33]. Comparing the cytotoxicities of recombinant 
proteins and indicated cancer drugs (DOX, bevacizumab, paclitaxel liposome) was done in 
MCS using a growth inhibition assay [34]. The MCS of about 200 µm in diameter were 
incubated with different treatments, as indicated, at 37 °C for 7 days. As an indication of 
MCS proliferation, the diameters of spheroids were measured every day after images were 
taken using an optical microscope.
2.6. Penetration in MCS and in tumor tissue
The distributions of anti-EGFR and anti-EGFR-iRGD in MCS were determined by LSCM. 
For each experiment, around 20 BGC-823 spheroids (about 200 µm in diameter) were 
collected and transferred to a 5 mL Eppendorf tube. MSC were incubated with FITC-labeled 
anti-EGFR and anti-EGFR-iRGD for 6 h or 24 h at 37 °C. Proper concentrations of proteins, 
DOX and DOX combination with indicated proteins were added respectively, to the 
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suspension of spheroids, and co-cultured for the indicated time. Coumarin-6 loaded 
poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles (PEG-PCL-Coumarin-6-NP) were 
prepared as previously described [35]. Similarly, proper concentrations of proteins, PEG-
PCL-Coumarin-6-NP and PEG-PCL-Coumarin-6-NP combination with indicated proteins 
were added respectively. The semi-quantitative analysis of mean fluorescence intensity of 
MCS was made using the ZEN 2008 program.
Due to overexpression of EGFR, NRP-1 and integrin in BGC-823 cells (Supplementary Fig. 
S3A, B, and C), H22 bearing ICR mice were used as models to evaluate iRGD effects 
[34,36]. We made use of two animal models to trace the location of proteins and investigate 
the penetration of recombinant proteins. BALB/c mice and ICR mice were subcutaneously 
inoculated with either BGC-823 cells or H22 cells, when tumors reached about 400 mm3, 
the FITC-labeled anti-EGFR and anti-EGFR-iRGD were injected into BGC-823 tumor-
bearing mice and H22 tumor-bearing mice via a tail vein, respectively. Mice were sacrificed 
and tumors were harvested 1 h after administration. Immunofluorescence for frozen tumor 
tissue sections was conducted as previously described [34,36,37]. The sections were 
observed with LSCM.
2.7. In vivo antitumor effect and safety of anti-EGFR and anti-EGFR-iRGD
BALB/c mice were subcutaneously injected with BGC-823 gastric cancer cells as mentioned 
above. The mice with tumors of about 100 mm3 were randomly divided into 4 groups with 
each group containing 8 mice (no statistically significant difference in tumor volume among 
groups). The day of randomization was designated as “Day 0”. Proteins were diluted in PBS 
at 1.2 mg/mL, and the mice were treated by intraperitoneal injection every 3 days with 
recombinant protein anti-EGFR, anti-EGFR-iRGD or cetuximab at 12 mg/kg on the first day 
of treatment (day 0) and either 6 mg/kg or PBS each subsequent injection. The injections 
were given every 3 days (a total of 4 injections in the BGC-823 model). All of the mice were 
observed daily and the body weight and tumor volume (by a digital vernier caliper) were 
measured every 3 days. Mice were sacrificed at the end of the experiment. Both tumor 
tissues and main organs (heart, liver, spleen, lung and kidney) were dissected for histology 
observation on the 12th day after treatment (n = 3 mice per group). After being fixed in 10% 
neutral buffered formalin, the tissues were embedded in paraffin, sectioned at a thickness of 
5 µm, and stained by H&E (hematoxylin and eosin). The proliferating cell nuclear antigen 
(PCNA) immunohistochemistry was used to evaluate the proliferation of the cells in the 
tumors. The slices obtained were examined using optical microscopy.
3. Results
3.1. Construction, production and characterization of recombinant protein
Anti-EGFR and anti-EGFR-iRGD genes were separately cloned in frame between the NcoI 
and HindIII restriction sites of the pET28a plasmid, from which recombinant proteins 
containing His tag were produced (Fig. 1A). Most of the recombinant proteins were detected 
as soluble proteins (Fig. 1B and C), successfully induced in E. coli BL21 (DE3) and purified 
respectively. Proteins migrated as major bands at 16 kDa (anti-EGFR) and 18 kDa (anti-
EGFR-iRGD) in Coomassie blue-stained SDS-PAGE (Fig. 1B and C). The molecular weight 
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of anti-EGFR and anti-EGFR-iRGD was detected as 16171 and 18050 by MALDI-TOF 
(data not shown), which is consistent with the values expected from the recombinant protein 
sequence. These results confirm the successful expression of soluble anti-EGFR and anti-
EGFR-iRGD.
The sequence identity between anti-EGFR and B39 VHH was 76.8% (Supplementary Fig. 
S1), while linker G4S and iRGD had no template. The 3D structures were then constructed 
by homology modeling using B39 VHH as the template to determine whether iRGD could 
influence the structure of the sdAb. Molecular dynamics simulations were conducted to 
refine the models. Linker G4S and iRGD stationed at the outside of anti-EGFR, as a 
consequence did not intertwine with the sdAb (Fig. 1D and E). When superimposed, most 
regions of anti-EGFR overlapped very well with anti-EGFR of anti-EGFR-iRGD (Fig. 1F), 
and showed no obvious difference from the overall structure of the sdAb. The root mean 
square deviation of Cα is 1.757 Å, which implies that the iRGD motif does not affect the 3D 
structure of the sdAb.
3.2. Evaluating the antigen-binding profiles of recombinant proteins
The binding profiles of recombinant protein anti-EGFR and anti-EGFR-iRGD were 
analyzed using the SPR-based biosensor by flowing them separately over the same surface 
of human EGFR-extracellular domain (Supplementary Fig. S2). The kD of anti-EGFR and 
anti-EGFR-iRGD was in the same order of magnitude (Supplementary Table S1), which 
means the modification of anti-EGFR would not affect its biological activity, i.e., the iRGD 
domain would not weaken the affinities to EGFR of anti-EGFR-iRGD.
The indicated treatments for the best silencing effects (50 nM of EGFR siRNA-No. 1, 50 nM 
of αvβ3 siRNA-No. 1, and 50 nM of NRP-1 siRNA-No. 2) were conducted following the 
manufacturer's description of Lipofectamine® 2000. The silencing effects were confirmed 
by Western blotting (Supplementary Fig. S3A, B and C). It was found that BGC-823 cells 
co-incubated with the EGFR, αvβ3, and NRP-1 siRNA took up less anti-EGFR-iRGD-FITC 
than the negative control (NC) siRNA group (Fig. 2A). When the fluorescence intensity for 
the NC siRNA was set at 100%, the fluorescence intensity was 59.0% for EGFR siRNA, 
88.8% for αvβ3 siRNA, and 77.6% for NRP-1 siRNA. It can be seen from the first panel 
(NC siRNA) that the strong green fluorescence of anti-EGFR-iRGD was located in the 
cytoplasmic region with a diffused pattern, indicating that a large number of the proteins 
were internalized in the cells (Fig. 2C). These results indicate that the recombinant protein 
anti-EGFR-iRGD possesses specificity and affinity to EGFR, αvβ3, NRP-1 and could 
internalize into cells.
Furthermore, the specificity and affinity of anti-EGFR-iRGD binding to the target antigen 
were assessed using a competitive binding assay. When fluorescence intensity for anti-
EGFR-iRGD-FITC taken up by BGC-823 was set as 100%, the affinity of anti-EGFR-iRGD 
was decreased to 85.7% or 85.2% when 25 µg/mL of cetuximab or 10 µg/mL of iRGD final 
concentration was added to compete with the antigen (Fig. 2D). The binding of anti-EGFR-
iRGD to BGC-823 cells was specifically inhibited by both cetuximab and iRGD, indicating 
that anti-EGFR-iRGD binds to the same receptor. These results indicate that anti-EGFR-
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iRGD possesses specificity and affinity to EGFR and is internalized through the same route 
as iRGD.
3.3. In vitro cytotoxicity, mechanism of recombinant proteins
To verify the pharmacological activity of anti-EGFR and anti-EGFR-iRGD, in vitro 
cytotoxicity tests using MTT assays against BGC-823, Caco-2 and MCF-7 (EGFR lowly 
expressed) [38] were conducted. It was found that both anti-EGFR and cetuximab exhibited 
no anti-proliferative activity against BGC-823 cells even at the highest concentration of 240 
µg/mL (Fig. 3A). However, a dose-dependent cytotoxicity was observed for anti-EGFR-
iRGD. This finding indicates that the addition of the iRGD motif can improve the anti-
proliferative activity of anti-EGFR in the human gastric cancer cell line BGC-823. For the 
Caco-2 cell line (Fig. 3B), anti-EGFR and anti-EGFR-iRGD showed notable anti-
proliferative activity compared with cetuximab. Although the difference between anti-EGFR 
and anti-EGFR-iRGD was not significant, anti-EGFR-iRGD exhibited a slightly stronger 
inhibition in proliferation of Caco-2 (p = 0.076). For the MCF-7 cell line (low EGFR 
expression), no anti-proliferative activity was observed even at the highest concentration of 
240 µg/mL (Fig. 3C).
To evaluate the mechanism of recombinant proteins inhibiting cancer cell proliferation, 
indicated concentrations of anti-EGFR, anti-EGFR-iRGD or cetuximab were added to 
BGC-823 cells. The cells were harvested 20 h later and the protein expression level for 
EGFR and active p-EGFR (Tyr1172) were analyzed using a Western blot. It was found that 
the phosphorylation of EGFR can be inhibited by all of the 50 µg/ml protein treatments 
indicating that anti-EGFR and anti-EGFR-iRGD may act like cetuximab in inhibiting EGFR 
Tyr1172 phosphorylation, thus inhibiting cancer cell proliferation (Supplementary Fig. 
S3D).
3.4. MCS growth inhibition and penetration in MCS for protein alone
BGC-823 was also used to culture the 3D tissue model called MCS. It was observed that the 
MCS had a symmetrical and spherical shape of about 200 µm in diameter after 7 days in 
culture (Fig. 4A). To study the inhibition of different treatments to MCS, BGC-823 MCS 
were exposed to culture medium and the recombinant protein groups (120 µg/mL) for 24 h 
and then incubated with fresh culture medium (changed every day) for another 6 days. The 
representative images of MCS that underwent different treatments indicate that MCS in the 
fresh culture medium and protein groups all grew during the 7 day period (Fig. 4B). It was 
found that the cells of MCS became very compact due to the interaction among cells and the 
secretion of ECM.
The alteration in mean diameter of all 4 groups can be seen in Fig. 3D. It indicates that the 
culture medium control group and anti-EGFR group, increased in diameter from 217 to 295 
µm and 202 to 261 µm, respectively. The diameter of both anti-EGFR-iRGD and cetuximab 
increased more slowly over time leading to a mean diameter of 232 µm and 240 µm, 
respectively. It is notable that the difference in mean diameter on day 7 between both anti-
EGFR-iRGD and cetuximab with the control is significant (p < 0.05).
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The penetration ability of recombinant protein anti-EGFR and anti-EGFR-iRGD was also 
analyzed with MCS. At 6 h, the fluorescence signal of anti-EGFR was only localized in the 
vicinity of the periphery of MCS, while the penetration of anti-EGFR-iRGD was deeper 
than that of anti-EGFR (Fig. 4C). After 24 h of incubation, the strong fluorescence of two 
recombinant proteins occupied the entire MCS. For anti-EGFR at 24 h, a gradually diffused 
and decreased fluorescence pattern from the periphery to center region of the spheroids was 
evident (Fig. 4C & D). On the other hand, the fluorescence pattern of anti-EGFR-iRGD 
grew in intensity from the periphery to center region of the MCS (Fig. 4C & D). This 
demonstrates that when anti-EGFR is fused with iRGD, the penetration in MCS is 
significantly improved.
3.5. MCS growth inhibition and penetration in MCS for protein combined with cancer drugs
In order to investigate whether combined with anti-EGFR-iRGD could enhance the efficacy 
of other cancer drugs, we tested chemical drugs from a 0.6 kDa molecule up to 
nanoparticles. To be specific, chemical drug DOX (20 µg/mL), monoclonal antibody 
bevacizumab (1 mg/mL) and liposomes (1.5 µg/mL) were used. The alteration of day 7 from 
day 1 in mean diameter of groups (proteins, DOX, bevacizumab, paclitaxel liposomes) can 
be seen in Fig. 5A and B (DOX); C (bevacizumab) and D (liposomes) are part of Fig. 5A. 
The control group (147% of original spheroid volume on 7th day) kept growing, and the 
inhibition of spheroid growth by protein anti-EGFR (100 µg/mL), anti-EGFR-iRGD (100 
µg/mL) and cetuximab (100 µg/mL) displayed a similar trend to the results of Fig. 3D. The 
treatments of DOX alone and combination groups inhibited growth of spheroids to a certain 
extent, the mean diameters from day 1 to day 7 were 203–206 µm for DOX, 204–196 µm for 
DOX combination with anti-EGFR, 200–142 µm for DOX combination with anti-EGFR-
iRGD, and 199–174 µm for DOX combination with cetuximab (Fig. 5B). These results 
indicate that combination of anti-EGFR-iRGD with DOX can more efficiently inhibit the 
growth of BGC-823 MCS (p < 0.01).
The inhibition of spheroid growth by bevacizumab groups exhibited a similar trend to the 
result of DOX. It indicates that the bevacizumab group, bevacizumab + anti-EGFR, 
bevacizumab + anti-EGFR-iRGD and bevacizumab + cetuximab increased in diameter from 
208 to 267 µm and 201 to 210 µm, and from 204 to 212 µm and 201 to 222 µm, respectively. 
It is notable that the difference in mean diameter on day 7 between both bevacizumab + anti-
EGFR-iRGD and bevacizumab + anti-EGFR with bevacizumab was significant (p < 0.01). 
For paclitaxel liposomes of size of about 400 nm, no significant difference is observed from 
these four groups, which means no protein could enhance the anti-cancer property of 
liposomes.
Here, we also tested whether the conjugation of iRGD to the C-terminus of anti-EGFR could 
enhance the penetration of DOX and nanoparticles into MCS by LSCM. From Fig. 6A, the 
penetration of DOX in the BGC-823 MCS at 2 h was limited to the outer few cell layers of 
the spheroids. The fluorescence signal of DOX combination with anti-EGFR or cetuximab 
group was similar to DOX alone. At 4 h, the weak fluorescence signal of DOX delivered 
together with anti-EGCR-iRGD started appearing at the center of the MCS with strong 
fluorescence appeared in few outer cell layers. This indicates that some DOX could 
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penetrate through the spheroids compared to DOX alone. After 8 h of co-incubation, a 
strong DOX fluorescence signal was observed spreading the whole MCS. A semi-
quantitative analysis of mean fluorescence intensity of DOX in MCS indicated that anti-
EGFR-iRGD could penetrate in BGC-823 MCS, and enhance DOX penetration into deeper 
zone of MCS (p < 0.001) (Fig. 6C). This is consistent with the result we observed in the 
growth inhibition in multicellular spheroids described above.
Coumarin-6 loaded PEG-PCL nanoparticles were prepared, and intracellular incorporation 
and release of coumarin-6 in BGC-823 MCS was measured by LSCM (Fig. 6B). At 2 h, the 
penetration of nanoparticles in the MCS was also limited to the outer few cell layers of the 
spheroids, which showed barely detectable levels of intracellular fluorescence. After 4 h of 
incubation, MCS incubated with anti-EGFR-iRGD + PEG-PCL-Coumarin-6-NP were more 
intensely fluorescent and showed deeper penetration of fluorescence than other groups. At 6 
h, the differences of fluorescence intensity between anti-EGFR-iRGD + PEG-PCL-
coumarin-6-NP and other groups were significant (Fig. 6D). We conclude that anti-EGFR-
iRGD can enhance PEG-PCL nanoparticle penetration into MCS.
3.6. Penetration in tumor tissue
Next, we analyzed the penetration ability of the anti-EGFR-iRGD by using both BGC-823 
bearing mice (Fig. 7) and H22 bearing ICR mice tumor tissue (Supplementary Fig. S4). 
Green fluorescence signal on LSCM images indicates recombinant protein's position as anti-
EGFR and anti-EGFR-iRGD were labeled with FITC. In order to visualize the location of 
blood vessels, Alex-594-conjugated secondary antibody was complexed with primary anti-
CD31 antibody. Thus, the blood vessels would exhibit red fluorescence. After 1 h post-
injection, anti-EGFR was observed and localized in the vicinity of blood vessels. This result 
indicates that anti-EGFR sdAbs can target the tumor and extravasate through the vessels. In 
contrast, anti-EGFR-iRGD penetrated much farther from the tumor vessels and even 
localized on a much larger area in the tumor tissue compared to anti-EGFR, and the FITC 
fluorescence mean intensity of anti-EGFR-iRGD was four times stronger than that of anti-
EGFR (Fig. 7B). H22 tumor tissues showed similar results to BGC-823 tumor tissue data. 
These data support the notion that iRGD as a functional group mediates active tumor 
penetration of the anti-EGFR protein. The result is consistent with the results of protein 
penetration in BGC-823 MCS (Fig. 4C & D).
3.7. Inhibitory effect of anti-EGFR-iRGD on tumor growth in mice and side effects study
We next sought to determine whether anti-EGFR-iRGD could be used as a therapeutic agent 
in the mice bearing subcutaneously inoculated BGC-823 tumors. Fig. 8A shows the growth 
curves of the BGC-823 tumors in the mice after the treatment has begun. The BGC-823 
tumors grew rather rapidly in mice treated with intraperitoneal injections of PBS or anti-
EGFR. By day 12, the average tumor volumes of PBS and anti-EGFR had increased about 
10 fold and 8 fold, respectively. In the cetuximab treated mice the tumor volume increased 
about 6 fold by day 12 and the tumor volume was reduced by about 31.5% compared to the 
PBS control group. Significantly, in the anti-EGFR-iRGD treated mice, the tumor volume 
increased 4.5 fold by day 12 and the tumor volume was reduced by about 63.7% compared 
with the PBS control group. The differences in tumor volumes between the groups treated by 
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anti-EGFR-iRGD and either PBS (p < 0.01) or anti-EGFR (p < 0.05) were both statistically 
significant.
None of the mice treated by intraperitoneal injection with PBS, anti-EGFR or cetuximab 
alone showed any body weight loss (Fig. 8B). Although the mean body weight of the anti-
EGFR-iRGD group showed a slight decrease during the treatment, the differences in body 
weight between the groups treated by anti-EGFR-iRGD and other groups were not 
significant (p > 0.05).
The pathology examination clearly demonstrated tumor necrosis present in the different 
treatments (Fig. 8C & E). In the control group treated with PBS, there were few necrotic 
regions. The anti-EGFR and cetuximab treated groups showed much larger necrotic regions, 
and the anti-EGFR-iRGD group was observed with the largest area of necrotic regions 
which explains the smallest tumor volumes of the group at the pathological level. In 
agreement with the H&E staining, there were many tumor cells stained positively with 
PCNA (cells with brown nuclei) in the control group, indicating a high proliferation ability 
(Fig. 8D & F). The anti-EGFR and cetuximab treated groups exhibited fewer positive cells 
compared to the control group. Tumors from the anti-EGFR-iRGD group showed the lowest 
number of positive cells. No abnormal damage was observed in the H&E stained sections of 
the main organs (Supplementary Fig. S5).
4. Discussion
In this study, we introduced a cell-penetrating peptide (CPP), iRGD, to an EGFR sdAb and 
evaluated the penetration and anti-proliferation activity on gastric cancer. CPPs allow 
cargoes such as small molecular drugs or nanoparticles to be internalized through the cell 
membrane [39]. HIV-Tat [40,41] is a traditional cell-penetrating peptide without cell 
selectivity, and most CPPs are nonspecific. The specificity of CPP can be supplemented by 
combination with tumor-targeting peptides. Other kinds of CPPs have an inherent tumor 
targeting capacity, such as peptides with RGD (arginine/glycine/aspartic acid) or NGR 
(asparagine/glycine/arginine) sequences. Peptides such as iRGD, iNGR (CRNGRGPDC, 
iNGR) [42] or LyP-1 (CGNKRTRGC) [43] have both tumor-targeting and cell penetrating 
abilities. iRGD binds to the tumor marker integrin αvβ3 directly, while iNGR binds to CD13 
of the tumor vessels [42], and LyP-1 binds to a mitochondrial protein p32/gC1qR/HABP1 
[44] expressed at the cell surface of tumors. The peptide iRGD homed tumor cells or tumor 
vessels, and penetrated into the tumor cell or the tumor mass. Due to this activity, we 
introduced iRGD to the anti-EGFR sdAb in order to enhance the antitumor activity of the 
drug.
In the current study, the anti-EGFR sdAb and anti-EGFR-iRGD were both expressed 
successfully in E. coli BL21 (DE3) and purified by nickel–nitrilotriacetic acid affinity 
chromatography. Our results placed anti-EGFR in the N-terminal domain and iRGD in the 
C-end with a linker of Gly4Ser in between. This is the first demonstration of a recombinant 
protein constructed by introducing sdAb to iRGD. Surface plasmon resonance analysis, an 
antigen–antibody binding assay and a competitive binding assay revealed that anti-EGFR-
iRGD has two target antigens — EGFR and αvβ3. Most antibodies have only a single target, 
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however, bispecific antibodies (BsAbs) with specificity for two target antigens are preferred 
[45]. One type of BsAb can build a bridge between an immune cell and cancer cell 
facilitating cell death. Another kind of BsAb can bind to two growth factor receptors 
expressed on tumor cells and has the advantage of generating synergistic activities [46]. 
EGFR and integrin (αvβ3) are receptors expressed in many tumors [8,18]. Dual targeting of 
EGFR and αvβ3 has a wider scope of application for amplifying tumor targeting than either 
mechanism alone.
Instead of two-dimensional monolayer cells (2D), multicellular spheroids (3D) culture and 
in vivo studies were used to investigate the cell cytotoxicity and penetration of the 
recombinant proteins. These results revealed that both anti-EGFR and anti-EGFR-iRGD had 
anti-proliferation activity, especially on the cells that highly express EGFR, and that the 
latter showed stronger antitumor activity. Anti-EGFR-iRGD could penetrate into deeper 
zone of the MCS and tumor mass. The molecular mechanism of the rapid tumor tissue 
penetration of iRGD remains to be elucidated. However, several lines of evidence suggest 
that it may involve the so-called vascular permeabilization in the tumor induced by the 
CendR property of iRGD. Molecules such as VEGF-165 and some semaphorins that have 
exposed CendR motifs increase vascular permeability [47,48]. This novel agent shows great 
superiority in treating gastric tumor-bearing mice, and no significant abnormal damage was 
observed. What is more, anti-EGFR-iRGD also promoted DOX, PEG-PCL nanoparticles 
penetration into MCS and enhanced the efficacy of cancer drugs DOX, bevacizumab. For 
PEG-PCL-Coumarin-6-NP, NP + anti-EGFR-iRGD showed strongest fluorescence intensity 
of all groups (Fig. 6B & D). However, there was no significant difference of diameter of 
MCS between paclitaxel liposome combination with anti-EGFR-iRGD and other 
combination groups. The reason of this phenomenon is probably the size of the 
nanoparticles. The mean size of PEG-PCL-NP is around 100 nm [35], but the mean size of 
paclitaxel liposome is much bigger (~400 nm). Thus, anti-EGFR-iRGD could not efficiently 
deliver paclitaxel liposome into deep zone of MCS.
Chen et al. [49] defined and constructed a recombinant protein iRGD-CDD, they confirmed 
iRGD-CDD spread extensively within the tumor and demonstrated CendR peptide iRGD 
could be active in protein transduction. Similarly, the fusion protein anti-EGFR-iRGD in our 
work is a promising antitumor agent capable of spreading within both MCS and tumor tissue 
after intravenous injection. When using MCS, the results regarding protein penetration 
demonstrated the improved penetration of anti-EGFR in MCS when fused with iRGD. MCS 
are models that reflect many of the properties of natural solid tumors. Integrin expression, 
such as αvβ3, in MCS is more similar to nude mice xenotransplant expression than the high 
expression levels found in monolayers [50]. Integrin expression has been found to be limited 
in the proliferating periphery cell layers or quiescent intermediate zone [25]. Thus MCS are 
an ideal model for studying this targeting integrin protein, anti-EGFR-iRGD. Since there is 
no vasculature system in BGC-823 MCS, the iRGD-induced penetration should result from 
neuropilin-1 (NPR-1) expressed on BGC-823 cell membrane. As Sugahara et al. mentioned, 
when the iRGD binds to NRP-1, a cell internalization and trans-tissue transport pathway is 
activated [19].
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The therapeutic efficacy of anti-cancer drugs can be limited by poor penetration into tumors 
due to the complicated tumor microenvironment. It was found that chemical conjugation 
with iRGD is not required to enhance the therapeutic effects of anticancer drugs. Systemic 
injection with free iRGD into the mouse tumor models can enhance tumor-specific delivery 
and improve the therapeutic index of 10 different anti-cancer drugs including DOX, 
trastuzumab and nanoparticles (from a 0.6 kDa molecule up to a 130 nm particle) [37]. In 
the present work, the iRGD domain was set in the C-terminal and conjugated with a 
relatively large sdAb. The molecular weight of anti-EGFR is 16.17 kDa, while iRGD 
contains only 9 amino acids. Due to the linker (Gly4Ser)3, the 3D structure of anti-EGFR-
iRGD, investigated by molecular modeling, shows that the iRGD motif does not influence 
the structure of the sdAb. In addition, anti-EGFR does not impact the function of iRGD 
including the affinity of cyclic-RGD for integrin αvβ3 and its vascular and tissue 
permeability. We propose that anti-EGFR-iRGD can help improve the performance of 
cancer drugs, and we are currently continuing the research on the in vivo efficacy of anti-
EGFR-iRGD helping both anti-cancer drugs and tumor imaging agents. This is the first time 
comparing the delivery efficiency of this combination regimen to that of the iRGD fusion 
protein.
5. Conclusion
In summary, this study represents an example of constructing a fusion protein of peptide 
iRGD and sdAb. We expressed and investigated the therapeutic efficacy of anti-EGFR-iRGD 
on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first 
time. This novel agent shows great superiority in treating solid tumors, especially for gastric 
cancer, and could be a useful adjunct of other anti-cancer drugs. We are currently continuing 
the research of the co-administration of anti-EGFR-iRGD and other anticancer drugs or 
tumor imaging agents for gastric cancer and other solid tumors. There are still issues to be 
addressed, e.g., stability and pharmacokinetic properties of the recombinant proteins, and the 
mechanisms underlying the antitumor efficacy of anti-EGFR-iRGD which will be further 
studied to guarantee improved clinical application.
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Expression and purification analysis of recombinant proteins anti-EGFR and anti-EGFR-
iRGD. A, restriction sites are indicated underlined, the His × 6 tag and G4S tag are shown in 
the boxes. B and C, anti-EGFR and anti-EGFR-iRGD purified from BL21 (DE3) lysate. 
Lane 1: bacterium without IPTG introduction; Lane 2: bacterium introduced with 1 mM 
IPTG at 37 °C; Lane 3: the precipitation of the ultrasonic lysate; Lane 4: the supernatant of 
the ultrasonic lysate; Lane 5: purified anti-EGFR (B) or anti-EGFR-iRGD (C) with nickel-
affinity chromatography. D and E, the structures of the recombinant proteins anti-EGFR (D) 
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and anti-EGFR-iRGD (E) after homology modeling and molecular dynamics simulations. F, 
superimposition of anti-EGFR and anti-EGFR-iRGD.
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Evaluating the antigen-binding profile of recombinant protein anti-EGFR-iRGD. A and C, 
after transfection with siRNA to silence the expression of EGFR, αvβ3 or NRP-1, the 
binding profile of BGC-823 cells with FITC labeled anti-EGFR-iRGD was analyzed by flow 
cytometry analysis (A) and LSCM (C). B and D, the analyses of BGC-823 tumor cells by 
competitive binding assay are shown according to FITC labeled anti-EGFR-iRGD. 
BGC-823 cells were incubated with a sub-saturating concentration of anti-EGFR-iRGD-
FITC and an indicated concentration of competing mAb cetuximab or iRGD. The 
fluorescence images (D) are shown and the alterations of the mean channel fluorescence on 
the surface of BGC-823 cells were detected by flow cytometry analysis (B). Scale bar in C = 
20 µm and D (×400).
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Cytotoxicity of protein anti-EGFR or anti-EGFR-iRGD in tumor cell lines and MCS. A, B 
and C, anti-EGFR, anti-EGFR-iRGD, or cetuximab of various concentrations were added to 
the BGC-823 (A), Caco-2 (B) or MCF-7 (C) cell suspensions and incubated for 48 h. Cell 
viability was measured by MTT assay. D, growth inhibition assay in BGC-823 MCS. 
Growth curves of MCS after various indicated treatment. All data were expressed as the 
mean ± standard deviation (SD), n = 4. Data represent the means of three independent 
experiments. Statistical analyses were performed using the Student t test and one-way 
ANOVA. *, p < 0.05, **, p < 0.01, ns, not significant.
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The image of BGC-823 MCS and the penetration of proteins in BGC-823 MCS. A, the 
image of BGC-823 MCS captured by an optical microscope; scale bar = 200 µm. B, 
representative images of MCS treated with culture medium, anti-EGFR, anti-EGFR-iRGD 
or cetuximab. MCS were cultured in RPMI 1640 medium as a control; scale bar = 100 µm. 
C, LSCM images of BGC-823 MCS incubated with FITC-labeled anti-EGFR and FITC-
labeled anti-EGFR-iRGD for 8 h and 24 h. D, the alterations of the mean fluorescence 
intensity from the center region to the periphery of the MCS cultured with anti-EGFR-FITC 
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and anti-EGFR-iRGD-FITC after 24 h incubation. Data are represented as mean ± SD (n= 
3). ***, p < 0.001. Scale bar in C, 50 µm.
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Growth inhibition assay in BGC-823 MCS. Growth curves of MCS after various indicated 
treatment. B, C and D are part of A. All data were expressed as the mean ± standard 
deviation (SD), n = 4. Data represent the means of three independent experiments. Statistical 
analyses were performed using the Student t test and one-way ANOVA. *, p < 0.05, **, p < 
0.01, ns, not significant.
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Penetration into MCS of DOX or PEG-PCL-Coumarin-6-NP combined with recombinant 
protein. A and C, LSCM images (A) and mean fluorescence intensity (C) of BGC-823 MCS 
incubated with DOX, DOX combined with anti-EGFR, DOX combined with anti-EGFR-
iRGD, DOX combined with cetuximab for 2 h, 4 h and 8 h, respectively. B and D, LSCM 
images (B) and mean fluorescence intensity (D) of BGC-823 MCS incubated with PEG-
PCL-Coumarin-6-NP, PEG-PCL-Coumarin-6-NP combined with anti-EGFR, PEG-PCL-
Coumarin-6-NP combined with anti-EGFR-iRGD, PEG-PCL-Coumarin-6-NP combined 
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with cetuximab for 2 h, 4 h and 8 h, respectively. Data are represented as mean ± SD (n = 3). 
**, p < 0.01. ***, p < 0.001. Scale bar in A = 50 µm, scale bar in B = 100 µm.
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Evaluation of the penetration of anti-EGFR (top) and anti-EGFR-iRGD (bottom) in 
BGC-823 tumors at 1 h post-injection. A, FITC labeled proteins (green) and CD31 of blood 
vessels (red) are shown in the images of tumor sections. Scale bar = 100 µm. B, the 
quantification of fluorescence intensity.
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Mice bearing subcutaneous BGC-823 (8 mice per treatment group) were treated by 
intraperitoneal injections of PBS, anti-EGFR, anti-EGFR-iRGD or cetuximab every three 
days. A and B, show the tumor growth curves (A) and bodyweight change (B) of BGC-823 
tumor-bearing mice that received the indicated treatments. Data are represented as mean ± 
SEM (standard error of the mean) (n = 8). One-way ANOVA was used for the analysis of 
tumor volume and body weight. *, p < 0.05, **, p < 0.01. C and D, show analysis for cell 
necrosis and anti-proliferative effect of anti-EGFR and anti-EGFR-iRGD in BGC-823 
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tumors. Cell necrosis was evaluated by H&E staining (×100 upper, ×200 lower) of tumor 
sections and cell proliferation was evaluated by immunohistochemistry of PCNA (D). *, 
indicate the necrotic regions. Scale bar = 100 µm. E and F, the quantification of tumor 
necrosis area (E) and PCNA immunohistochemical positivity (F).
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